GILD Gilead Sciences: Scotiabank Maintains Outperform, PT $177 Feb 2026

On February 11, 2026, Scotiabank and Bernstein both maintained Outperform on Gilead Sciences, Inc. (GILD). This GILD analyst rating news included Scotiabank raising its price target to $177 from $140, and Bernstein lifting its target to $160. Both firms left their Outperform stance unchanged, signaling continued confidence in Gilead’s pipeline and revenue mix. Investors should note that these are rating confirmations with higher valuation assumptions, not buybacks or guidance changes. Meyka AI provides this report as an AI-powered market analysis platform and Meyka AI rates GILD with a grade of B+. This grade factors in S&P 500 benchmarking, sector performance, financial growth, key metrics, and analyst consensus.

GILD analyst rating: Feb 11, 2026 updates from Scotiabank and Bernstein

Scotiabank on February 11, 2026 maintained Outperform and raised its Gilead price target to $177 from $140. See the Scotiabank note reported by The Fly source. Bernstein on the same date also maintained Outperform and raised its target to $160, per StreetInsider source. Both firms reiterated positive views on HIV franchise growth and pipeline upside.

What the maintained Outperform ratings mean for investors

A maintained Outperform means analysts expect Gilead to beat sector returns. It signals confidence rather than a fresh upgrade. Investors should view these actions as conviction in revenue growth and product launches. The higher price targets reflect refreshed valuation models and stronger long-term cash flow assumptions. These ratings do not guarantee stock moves and require due diligence.

GILD price target changes and immediate stock reaction

Scotiabank raised its target to $177, up $37 from $140. Bernstein raised its target to $160. The reports show small intraday moves: Scotiabank-linked news noted a 1.14% ($1.76) price change since the note, while Bernstein-linked news showed -0.04% ($-0.07). Analysts’ target lifts often drive short-term buying interest, but actual price trajectory depends on earnings, guidance, and trial updates.

Historical analyst coverage and context for Gilead Sciences

Gilead has carried strong coverage from major firms for years due to its HIV portfolio and oncology investments. Historically, top-tier brokers have alternated between Outperform and Market Perform as trial data and drug launches evolve. Recent upgrades of price targets indicate analysts are assigning higher multiples amid stable HIV sales and upcoming product catalysts. Long-term investor returns have tracked pipeline success and successful commercialization.

Meyka grade, market cap, and valuation implications

Meyka AI rates GILD with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Gilead’s market cap stands at $193,297,885,263. Higher price targets from Scotiabank and Bernstein push implied upside, but investors should weigh valuation against pipeline risk and near-term sales momentum.

Key catalysts and what investors should watch next

Watch upcoming clinical updates such as the Phase III IDEAL study and Yeztugo launch traction. Monitor quarterly guidance and Q1 2026 sales trends for HIV products. Track any further analyst commentary that revises assumptions on margin expansion or royalty receipts. Use these catalysts to judge if the maintained Outperform ratings warrant portfolio action.

Final Thoughts

The February 11, 2026 notes from Scotiabank and Bernstein kept the same positive stance on Gilead Sciences, Inc. (GILD) by maintaining Outperform while raising price targets to $177 and $160 respectively. These moves show analyst confidence in Gilead’s commercial execution and clinical pipeline. For investors, a maintained Outperform with higher targets means analysts see improved valuation levers, not a change in fundamental sentiment. Short-term price response varied, with a 1.14% ($1.76) move noted on Scotiabank-linked coverage and minimal change on Bernstein’s note. Weigh these updates against Gilead’s upcoming trial readouts and revenue guidance. Meyka AI rates GILD with a grade of B+; this grade balances benchmark performance, sector peers, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Use this analysis to inform, not replace, your personalised research and risk assessment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.